Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
Antonio M. Gotto,Edwin J. Whitney,Evan A. Stein,Deborah R. Shapiro,Michael Clearfield,Stephen E. Weis,Jesse Y. Jou,Alexandra Langendorfer,Polly A. Beere,Douglas J. Watson,John R. Downs,John S. de Cani +11 more
Reads0
Chats0
TLDR
People with average TC and LDL-C levels and below-average HDL-C may obtain significant clinical benefit from primary-prevention lipid modification, and on-treatment apoB, especially when combined with apoAI to form the apOB/AI ratio, may be a more accurate predictor than LDL- C of risk for first AMCE.Abstract:
Background—The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) is the first primary-prevention study in a cohort with average total cholesterol (TC) and LDL cholesterol (LDL-C) and below-average HDL cholesterol (HDL-C). Treatment with lovastatin (20 to 40 mg/d) resulted in a 25% reduction in LDL-C and a 6% increase in HDL-C, as well as a 37% reduction in risk for first acute major coronary event (AMCE), defined as fatal or nonfatal myocardial infarction, unstable angina, or sudden cardiac death. This article describes the relation between baseline and on-treatment lipid and apolipoprotein (apo) parameters and subsequent risk for AMCEs. Methods and Results—With all available data from the entire 6605-patient cohort, a prespecified Cox backward stepwise regression model identified outcome predictors, and logistic regression models examined the relation between lipid variables and AMCE risk. Baseline LDL-C, HDL-C, and apoB were significant predictors of AMCE; only on-treatment apoB...read more
Citations
More filters
Journal ArticleDOI
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
Gregory G. Schwartz,Anders G. Olsson,Michael D. Ezekowitz,Peter Ganz,Michael F. Oliver,David D. Waters,Andreas M. Zeiher,Bernard R. Chaitman,S. Leslie,Theresa Stern +9 more
TL;DR: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes and the MIRACL study are studied.
Journal ArticleDOI
ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina)
Raymond J. Gibbons,Jonathan Abrams,Kanu Chatterjee,Jennifer Daley,Prakash Deedwania,John S. Douglas,T. Bruce Ferguson,Stephan D. Fihn,Theodore D. Fraker,Julius M. Gardin,Robert A. O'Rourke,Richard C. Pasternak,Sankey V. Williams,Joseph S. Alpert,Elliott M. Antman,Loren F. Hiratzka,Valentin Fuster,David P. Faxon,Gabriel Gregoratos,Alice K. Jacobs,Sidney C. Smith +20 more
TL;DR: The Clinical Efficacy Assessment Subcommittee of the American College of Physicians–American Society of Internal Medicine acknowledges the scientific validity of this product as a background paper and as a review that captures the levels of evidence in the management of patients with chronic stable angina as of November 17, 2002.
Journal ArticleDOI
Triglycerides and Cardiovascular Disease A Scientific Statement From the American Heart Association
Michael Miller,Neil J. Stone,Christie M. Ballantyne,Vera Bittner,Michael H. Criqui,Henry N. Ginsberg,Anne C. Goldberg,William James Howard,Marc S. Jacobson,Penny M. Kris-Etherton,Terry A. Lennie,Moshe Levi,Theodore Mazzone,Subramanian Pennathur +13 more
TL;DR: The role of triglyceride-rich lipoproteins (TRLs) in the evaluation and management of CVD risk was discussed in this article, where the authors highlighted approaches aimed at minimizing the adverse public health-related consequences associated with hypertriglyceridemic states.
Journal ArticleDOI
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
Paul M. Ridker,Nader Rifai,Michael Clearfield,John R. Downs,Stephen E. Weis,J. Shawn Miles,Antonio M. Gotto +6 more
TL;DR: As expected, lovastatin was effective in preventing coronary events in participants whose base-line ratio of total cholesterol to high-de...
References
More filters
Journal ArticleDOI
Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge
TL;DR: A method for estimating the cholesterol content of the serum low-density lipoprotein fraction (Sf0-20) is presented and comparison of this suggested procedure with the more direct procedure, in which the ultracentrifuge is used, yielded correlation coefficients of .94 to .99.
Journal ArticleDOI
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more
TL;DR: Dairy therapy remains the first line of treatment of high blood cholesterol, and drug therapy is reserved for patients who are considered to be at high risk for CHD, and the fundamental approach to treatment is comparable.
Journal ArticleDOI
Prediction of Coronary Heart Disease Using Risk Factor Categories
Peter W.F. Wilson,Ralph B. D'Agostino,Daniel Levy,Albert M. Belanger,Halit Silbershatz,William B. Kannel +5 more
TL;DR: A simple coronary disease prediction algorithm was developed using categorical variables, which allows physicians to predict multivariate CHD risk in patients without overt CHD.
Journal Article
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Anders G. Olsson,Jjv McMurray,Gudmundur Thorgeirsson,C Spaulding,J Slattery,Kalevi Pyörälä,Ole Faergeman,RA Wright,Kåre Berg,Lars Wilhelmsen,Terje R. Pedersen,Tatu A. Miettinen,Harvey D. White,John Kjekshus,Michael Gnant +14 more
Journal ArticleDOI
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Frank M. Sacks,Marc A. Pfeffer,Lemuel A. Moyé,Jean L. Rouleau,John D. Rutherford,Thomas G. Cole,Lisa E. Brown,J. W. Warnica,J. M. O. Arnold,Chuan Chuan C Wun,Barry R. Davis,Eugene Braunwald +11 more
TL;DR: It is demonstrated that the benefit of cholesterol-lowering therapy extends to the majority of patients with coronary disease who have average cholesterol levels and was also greater in patients with higher pretreatment levels of LDL cholesterol.
Related Papers (5)
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more